Nuvalent, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Nuvalent, Inc. filed an 8-K report detailing the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. During the meeting, stockholders voted on three key proposals. First, Michael L. Meyers, M.D., Ph.D., and Ron Squarer were elected as Class II directors, with terms expiring at the 2029 annual meeting. Second, stockholders approved, on an advisory basis, the compensation paid to the company's named executive officers. Third, the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Approximately 96.80% of the outstanding Class A common stock was represented at the meeting. No significant clinical or operational updates were disclosed in this filing, which focused primarily on routine corporate governance and administrative matters.